AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05502432 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active repetitive transcranial magnetic stimulation
Description: Consecutive 15-day active treatment with 1 Hz of repetitive transcranial magnetic stimulation
Study NCT05502432 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham repetitive transcranial magnetic stimulation
Description: Consecutive 15-day sham treatment with 1 Hz of repetitive transcranial magnetic stimulation
Study NCT00781729 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Luncheon Seminar Series, once per month, for 24 weeks
Description: Luncheon Seminar Series, once per month, for 24 weeks
Study NCT02882360 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kerlix-AMD
Description: Application of PHMB impregnated gauze pre-operatively (for booked C-sections) and post-operatively for all patients with LSCS. Gauze to be changed daily or more frequently if damp/blood-tinged
Study NCT02882360 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo--normal gauze
Description: Application of gauze pre-operatively (for booked C-sections) and post-operatively for all patients with LSCS. Gauze to be changed daily or more frequently if damp/blood-tinged
Study NCT03655769 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation
Description: transcranial direct current stimulation applied at 2 mA over the right parietal region for 20 min
Study NCT03655769 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham transcranial direct current stimulation
Description: transcranial direct current stimulation applied at 2 mA over the right parietal region for 30 sec
Study NCT02060851 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: standard PN
Description: Group 1: a control group who received standard PN
Study NCT02060851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vifor
Description: iron sucrose, 200 μg/kg per day, was given everyday with PN,
Study NCT02060851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vifor and EPO
Description: EPO, 400U/kg, was given twice a week (Monday and Friday). IS, 200 μg/kg per day, was given everyday with PN, and the dose was continued until 2 weeks after birth
Study NCT03792126 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Implicit Learning Approach
Description: All mobility focussed rehabilitation sessions will utilise the Implicit Learning Approach (ILA), as usual care. This includes rehabilitation (delivered by a physiotherapist, occupational therapist or therapy assistant) that focusses on sitting, sit to stand, standing, stepping, transfers and walking. The content of therapy will be based on the treatment guidelines and intervention manual - and primarily involves changing the quantity and focus of attention of instructions and feedback.~As this is a clinically grounded, pragmatic trial, therapists will have freedom to tailor the specific content of each treatment session to patient need, whilst remaining true to the ILA.
Study NCT03419481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: 200mg every 3 weeks infusion
Study NCT04016090 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Folic Acid
Description: Folic acid (5 mg)
Study NCT01355575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin
Description: Rifaximin tablet, oral administration, 400mg twice daily for 6 weeks.
Study NCT03455101 — intervention group
Intervention type: OTHER
Intervention: There is no intervention.
Description: There is no intervention.
Study NCT04159454 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PITA
Description: Patients will have PITA turned on to patients' existing Medtronic devices, such that patients will be RV-paced from midnight to 6 AM each night at a rate \~10 beats per minute (BPM) above patients' baseline heart rates during this time period as determined by Holter monitors.
Study NCT02507141 — intervention group
Intervention type: DEVICE
Intervention: Reflectance Confocal Microscopy
Description: Reflectance Confocal Microscopy imaging will be performed during surgery. The imaging procedure is expected to last no more than 15-20 minutes. The approach will be essentially similar to the imaging of skin cancer on patients, which is routinely performed in our Dermatology Service.
Study NCT04850352 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Heukcha Extracts
Description: Experimental group: Heukcha Extracts
Study NCT04850352 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo group
Study NCT04589936 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prone positioning
Description: Patient will first lay supine for a given time period, followed by lateral position on either side, then prone position, lastly return to supine position. Participants are anticipated to stay in prone position for a minimum of 30min to a maximum of 2 hours depending on tolerability. Participants will be guided in how to independently position themselves and rotate through the cycle of positions.
Study NCT04589936 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Prone positioning
Description: Patient will first lay supine for a given time period, followed by lateral position on either side, then prone position, lastly return to supine position. Participants are anticipated to stay in prone position for a minimum of 30min to a maximum of 2 hours depending on tolerability. Participants will be guided in how to independently position themselves and rotate through the cycle of positions.
Study NCT04016090 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule
Study NCT01781728 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy (SBRT)
Description: Stereotactic Body Radiation Therapy (SBRT) which included 5 consecutive fractions of 25 to 33 Gy, following 3 months of multiagent chemotherapy.
Study NCT03860168 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: PICU Up!
Description: The PICU Up! intervention is a multifaceted mobility program incorporating the ABCDEF bundle components into routine PICU care through multidisciplinary staff education and a structured pathway to determine a patient's daily mobility goal. PICU Up! was developed by a collaborative multidisciplinary team approach, and the central components include the consultation and involvement of physical therapy/occupational therapy (PT/OT) by PICU Day 3, sleep hygiene promotion and routine delirium screening for all PICU patients utilizing a validated tool.
Study NCT01527929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel XRP6258
Description: Pharmaceutical form: solution for infusion Route of administration: intravenous
Study NCT01022762 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: repaglinide
Description: Individually adjusted dose for 16 weeks
Study NCT01022762 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gliclazide
Description: Individually adjusted dose for 16 weeks
Study NCT03595917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABL001
Description: •ABL001 is administered daily per 28 day cycle
Study NCT03595917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Fixed doses oral once a day per 28 day cycle
Study NCT03595917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Fixed doses oral once a day per 28 day cycle Prednisone will be tapered and stop during cycle 2.
Study NCT03595917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: By intravenous continuous infusion beginning no earlier than cycle 2 day 1 of protocol therapy Day 1-28 of each 42-day cycle, cycles 2-6, total of 5 cycles
Study NCT03215797 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: phenylephrine
Description: phenylephrine 100ug/ml IV infusion at a rate of 5ml/h in case of hypotension.
Study NCT03215797 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: phenylephrine
Description: phenylephrine 100ug/ml IV infusion at a rate of 5ml/h in case of hypotension.
Study NCT03215797 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Norepinephrine
Description: Norepinephrine 5ug/ml IV infusion at a rate of 5 ml/h in case of hypotension
Study NCT03215797 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine
Description: Norepinephrine 5ug/ml IV infusion at a rate of 5 ml/h in case of hypotension
Study NCT02411565 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fermented Wheat Germ Extract (FWGE)
Description: 5.53 grams of FWGE combined with natural orange flavor and stevia Reb-A sweetener to create an instant drink mix, dissolved in 150 mL of water, orally once-daily, for 2 to 4 weeks.
Study NCT02411565 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dried and pulverized, white and black rice, 5.53 grams, combined with natural orange flavor and stevia Reb-A sweetener, to create an instant drink mix, dissolved in 150 mL of water, orally once-daily, for 2 to 4 weeks.
Study NCT02411565 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care: Planned Surgery
Description: Participants will undergo their planned surgery during the 2nd to 4th week after entry into the study. However, if there are delays, patients can continue to take drug/placebo for a time period no greater than 2 months. If surgery has not occurred after this 2-month period, the patient will be removed from the study. Participants will take the study drug up until the day prior to surgery. The minimum amount of time on study drug is 2 weeks. A separate consent form will be obtained for the surgical procedure.
Study NCT02411565 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care: Planned Surgery
Description: Participants will undergo their planned surgery during the 2nd to 4th week after entry into the study. However, if there are delays, patients can continue to take drug/placebo for a time period no greater than 2 months. If surgery has not occurred after this 2-month period, the patient will be removed from the study. Participants will take the study drug up until the day prior to surgery. The minimum amount of time on study drug is 2 weeks. A separate consent form will be obtained for the surgical procedure.
Study NCT02411565 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality of Life (QoL) Surveys: FACT-O
Description: Quality of life questionnaire (FACT-O) at the time of enrollment, then weekly and the day of surgery.
Study NCT02411565 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Quality of Life (QoL) Surveys: FACT-O
Description: Quality of life questionnaire (FACT-O) at the time of enrollment, then weekly and the day of surgery.
Study NCT01845675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide or dacarbazine-based chemotherapy, endostatin
Study NCT01467180 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: septeX
Description: continuous veno-venose hemodialysis (CVVHD) with dialysate flow rate (Qd)of 35ml/kg/h for 48h
Study NCT01467180 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HF CVVH
Description: continuous veno-venose hemofiltration (CVVH) with 35ml/kg/h UF-rate for 48h
Study NCT03458572 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Seirin Pyonex press needle acupuncture
Description: Acupuncture
Study NCT03458572 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Seirin Pyonex press needle acupuncture
Description: Acupuncture
Study NCT01798329 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: probiotic VSL#3
Description: VSL#3 is a probiotic that reduces:~* urease faecal activity~* faecal pH~* inflammatory cytokine
Study NCT00913484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disulfiram
Description: Disulfiram 250 mg per day
Study NCT00913484 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo daily
Study NCT02961465 — intervention group
Intervention type: DEVICE
Intervention: Sacral Neuromodulation
Description: SNM starts with a screening phase. In this phase a tined lead is inserted into the third sacral foramen and attached to an external stimulator, after which the patient enters a four-week stimulation test period.~If the screening phase is successful (defecation frequency (DF) ≥3 a week), the external stimulator is changed for a pacemaker that is implanted in the buttocks. If the screening phase is unsuccessful (DF \<3 a week), the lead is explanted. Patients are asked to limit the use of additional conservative treatments for constipation (such as laxatives and colonic irrigation) to what is necessary to relieve (the most severe) complaints. What is necessary to relieve complaints is determined by the patient.
Study NCT03049410 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intracorporeal Robot Assisted Radical Cystectomy
Description: Intracorporeal robot assisted radical cystoprostatectomy or anterior exenteration
Study NCT03049410 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open Radical Cystectomy
Description: Removal of bladder and adjacent organs
Study NCT04086420 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: Received instructions to exercise at moderate intensity while listening to an audio-recorded mindfulness-based physical activity intervention
Study NCT04086420 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Heart-Rate
Description: Given a heart rate monitor, told to exercise within the moderate intensity range (64-76% of estimated maximum heart rate)
Study NCT03722134 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MOCA
Description: Great saphenous vein occlusion with a mechanochemical chateter which cause mechanical injury to vessel intima and gives sclerosant to the intima.
Study NCT03722134 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EVLA
Description: Great saphenous vein occlusion with a thermal laser chateter
Study NCT02619604 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Education Intervention
Description: Education interventions will be delivered sporadically within the 6-month window between the time the clinician completes the pre-survey and when he/she completes the post-survey. Interventions consist of e-brief publications, teleconferences with project faculty, and evidence based resources.
Study NCT00441584 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PegIntron (peginterferon alfa-2b)
Description: Powder for injection in vial or Redipen (50, 80, 100, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 48 weeks
Study NCT00441584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rebetol (ribavirin)
Description: 200 mg capsules, oral, weight based dose of 800-1400 mg, daily for up to 48 weeks
Study NCT04521400 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose Interferon-beta 1a
Description: High dose IFN-β1a (Recigen) (Subcutaneous injections of 88μg (24,000 IU) on days 1, 3, 6)
Study NCT04521400 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir/Ritonavir
Description: Lopinavir/Ritonavir (Kaletra) \[IFN-β1a group\] (400mg/100 mg twice a day for 10 days
Study NCT03722134 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RFA
Description: Great saphenous vein occlusion with a thermal radiofrequency chateter
Study NCT00127101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: Dose escalation study starting with vorinostat 200 mg q.d. capsules (1 capsule daily) and rising up to vorinostat 400 mg q.d. capsules (1 capsule daily). Up to 6 months of treatment.
Study NCT00127101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: bexarotene
Description: Dose escalation with bexarotene 150 mg/m2 capsules rising up to 300 mg/m2 capsules (1 capsule daily). Up to 6 months of treatment.
Study NCT04262518 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Outcomes4Me Mobile App
Description: A mobile app that provides patient navigation and treatment and clinical trial options to people with breast cancer
Study NCT01830127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 24 Weeks
Study NCT01830127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 207127 high dose
Description: 24 Weeks
Study NCT01830127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faldaprevir
Description: 24 Weeks
Study NCT01830127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 207127 low dose
Description: 24 Weeks
Study NCT04092374 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Locking compression plates
Description: Fixation of sternal fracture using locking compression mechanism
Study NCT03399695 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: preoxygenation
Description: spontaneous breathing
Study NCT03399695 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: preoxygenation
Description: spontaneous breathing
Study NCT02382198 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glycopyrrolate
Description: Drug to reduce drooling in patients with Parkinson's Decease.
Study NCT02382198 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03097705 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: OCT (Optical coherence tomography)
Description: RNFL AND IOP MEASUREMNTS
Study NCT03717896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200mg IV thiamine in 50mL 0.9% saline
Description: Thiamine 200mg IV every 12 hours for 2 days
Study NCT03717896 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 50mL 0.9% saline
Study NCT04625725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7442
Description: * Single dose (× 2IM injections) of 300 mg of AZD7442 on parent study Day 1.~* Single dose (× 2IM injections) of 300 mg of AZD7442 on sub-study Day 1.~* Single dose (× 2IM injections) of 300 mg of AZD7442 on sub-study Day 183.~* Single dose (x 2IM injections) of 600mg of AZD7442 on sub-study Day 183 and Day 366
Study NCT04625725 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose (× 2IM injections) of saline placebo on parent study Day 1.
Study NCT04538742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Description: T-DXd: administered as an IV infusion
Study NCT04538742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab: administered as an IV infusion
Study NCT04538742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel: administered as an IV infusion
Study NCT04538742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Pertuzumab: administered as an IV infusion
Study NCT04538742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tucatinib
Description: Tucatinib administered orally (tablet) twice daily
Study NCT05101239 — intervention group
Intervention type: DEVICE
Intervention: MRI imaging exam
Description: 3T MRI scan using with ultra high performance gradient subsystem (MAGNUS MRI)
Study NCT02228265 — intervention group
Intervention type: OTHER
Intervention: Cytology Specimen Collection Procedure
Description: Undergo blood and tissue collection
Study NCT02228265 — intervention group
Intervention type: DRUG
Intervention: Enzalutamide
Description: Given PO
Study NCT02228265 — intervention group
Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03491761 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRP Treatment
Description: PRP will be prepared using an Arthrex ACP® kit (a low-leukocyte Autologous Conditioned Plasma system). This is a single-spin system that concentrates platelets and separates red blood cells (RBCs) as well as white blood cells (WBCs) from the treatment product.
Study NCT03491761 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: HA Treatment
Description: Euflexxa will be used for treatment. It will be prepared according to the package insert.
Study NCT00313404 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Safety tested norovirus inoculum
Description: This is a safety tested live infectious norovirus inoculum that has been placed in groundwater that meets EPA drinking water standards
Study NCT01208454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotretinoin
Description: Given PO
Study NCT01208454 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01208454 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT01208454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Given PO